Mitigating Patient Risk in the Era of Highly Effective Antiobesity Medications

According to a KFF poll, about 1 in 8 U.S. adults aged 18 years or older have reported using glucagon-like peptide 1 agonists, otherwise known as GLP-1 medications. Originally developed to treat diabetes, they are now also FDA approved for chronic weight management, increasing their need and popularity among patients. As prescriptions for GLP-1 medications are on the rise, it’s essential for healthcare professionals to understand the risks and side effects of the popular drugs. Join Dr. Sarah Barenbaum, obesity medicine director of the GI Metabolic & Bariatric Surgery practice at Weill Cornell Medical College, for an update on GLP-1 medications for the treatment of obesity. Dr. Barenbaum will provide an informative presentation on what physicians – and patients – should know when prescribing and taking these medications.

Who can attend

Registration is limited to ISMIE and SEMPIC policyholders, ISMS members, and their employed staff.

Learning objectives

At the conclusion of this learning activity, participants will be able to:

• Review the mechanisms of the currently approved GLP-1 antiobesity medications and how to describe them to patients
• Discuss the common side effects of GLP-1 antiobesity medications and strategies to mitigate them
• Identify contraindications and more serious side effects of GLP-1 antiobesity medications
• Describe strategies for documenting conversations around GLP-1 antiobesity medications

About the presenter

Sarah Barenbaum, MD, is an assistant professor of clinical medicine at Weill Cornell Medical College. She serves as the obesity medicine director of the GI Metabolic & Bariatric Surgery practice, and as the program director of both the Obesity Medicine and the Obesity Medicine/Bariatric Endoscopy fellowship programs. Dr. Barenbaum received her BA from Yale University and her MD from Drexel University College of Medicine. Dr. Barenbaum completed a residency in Internal Medicine and a fellowship in Obesity Medicine at New York-Presbyterian/Weill Cornell Medicine. Dr. Barenbaum is board-certified in Internal Medicine and Obesity Medicine. Dr. Barenbaum specializes in the care of patients with obesity and weight-related medical complications, and she sees patients at both the Comprehensive Weight Control Center and the GI Metabolic & Bariatric Surgery program.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Illinois State Medical Society and ISMIE Mutual Insurance Company. The Illinois State Medical Society is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Illinois State Medical Society designates this live activity for a maximum of 1 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure

There are no relevant financial relationships with ACCME-defined commercial interests for anyone who was in control of the content of this activity.